Table 1 Baseline demographic and tumor characteristics for HNSCC patients receiving radiotherapy with or without concomitant cetuximab

Mean age at Diagnosis in years [SD]

65.51 (11.25)

65.71 (12.20)

65.31 (10.29)

0.821

Age group at Diagnosis in years (n (%))

<50

11 (6.4)

8 (9.4)

3 (3.5)

0.092

50-70

101 (59.1)

44 (51.8)

57 (66.3)

>70

59 (34.5)

33 (38.8)

26 (30.2)

Gender (n (%))

Female

37 (21.6)

18 (21.2)

19 (22.1)

1

Male

134 (78.4)

67 (78.8)

67 (77.9)

Race (n (%))

Black

50 (29.2)

23 (27.1)

27 (31.4)

0.822

White

117 (68.4)

60 (70.6)

57 (66.3)

Other

4 (2.3)

2 (2.4)

2 (2.3)

Median Total Charlson comorbidity index (range)

1 (0-3)

1 (0-2)

2 (1-3)

0.082

Smoking (n (%))

Never

30 (17.5)

15 (17.6)

15 (17.4)

0.918

Former

87 (50.9)

42 (49.4)

45 (52.3)

Active

54 (31.6)

28 (32.9)

26 (30.2)

Alcohol use (n (%))

Never

57 (33.3)

28 (32.9)

29 (33.7)

0.926

Occasional

52 (30.4)

25 (29.4)

27 (31.4)

Frequent

62 (36.3)

32 (37.6)

30 (34.9)

Tumor site (n (%))

Oral cavity

29 (17.0)

11 (12.9)

18 (20.9)

<0.001

Oropharynx

82 (48.0)

56 (65.9)

26 (30.2)

Hypopharynx

2 (1.2)

1 (1.2)

1 (1.2)

Larynx

58 (33.9)

17 (20.0)

41 (47.7)

Tumor staging (n (%))

Early

72 (42.1)

21 (24.7)

51 (59.3)

<0.001

Locally advanced

99 (57.9)

64 (75.3)

35 (40.7)

Tumor grade of differentiation (n (%))

Well

10 (7.5)

3 (4.7)

7 (10)

<0.001

Moderate

62 (46.3)

23 (35.9)

39 (55.7)

Poor

27 (20.1)

22 (34.4)

5 (7.1)

HPV status (oropharyngeal cancers) (n (%))

Positive

37 (64.9)

21 (58.3)

16 (76.2)

0.282

Negative

20 (35.1)

15 (41.7)

5 (23.8)